Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
291.1 GBX | -1.32% | -9.88% | -17.42% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.42% | 385M | |
+8.33% | 219B | |
+6.72% | 183B | |
+10.18% | 132B | |
+24.91% | 106B | |
-2.43% | 62.09B | |
+10.56% | 50.8B | |
+4.81% | 50.88B | |
-0.24% | 40.64B | |
+1.22% | 35.71B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- Transcript : MaxCyte, Inc., 2023 Earnings Call, Mar 12, 2024